Browse our comprehensive collection of market intelligence reports.
Multiple sclerosis (MS) remains one of the most active neuroimmunology pipeline markets because current disease-modifying therapies reduce inflammatory activity but provide limited restoration of neurological function and incomplete control of progressive disease. This treatment gap is driving sustained investment toward therapies that simultaneously target neuroinflammation, remyelination, neuroprotection, and immune tolerance. Clinical development therefore extends beyond conventional immun
The global multiple sclerosis (MS) pricing and reimbursement landscape is undergoing structural transformation as healthcare systems prioritize long-term disease control while managing rising expenditure on high-cost disease-modifying therapies (DMTs). Pricing strategies increasingly reflect clinical value, comparative effectiveness, real-world evidence, and long-term health economic outcomes rather than product novelty alone. Demand remains concentrated on therapies that demonstrate durable
The Global Multiple Sclerosis Emerging Therapies Report evaluates the evolving clinical pipeline for disease-modifying therapies, remyelination strategies, neuroprotective agents, and regenerative approaches that are addressing the unmet needs across relapsing and progressive forms of multiple sclerosis (MS). The report focuses on pipeline candidates, mechanisms of action, clinical development progress, regulatory trends, and sponsor strategies shaping innovation between 2026 and 2031. <
The global multiple sclerosis (MS) drug pipeline is entering a phase in which therapeutic innovation is extending beyond relapse control toward disability modification, neuroprotection, remyelination, and precision immune regulation. Development activity remains concentrated around progressive disease, where unmet clinical needs continue to shape investment priorities. Sponsors are expanding portfolios across biologics, oral small molecules, cell-based therapies, antigen-specific immune toler
The global multiple sclerosis (MS) pipeline is entering a phase in which clinical differentiation is becoming more important than expanding the number of investigational assets. Established disease-modifying therapies continue to control inflammatory disease activity, yet persistent disability progression, remyelination failure, and progressive forms of MS are sustaining demand for therapies with novel mechanisms of action. This shift is driving developers toward immune rebalancing, neuroprot
The global multiple sclerosis (MS) clinical trial landscape is entering a transition in which sponsors are moving beyond relapse control toward therapies that slow disability progression, preserve neurological function, and modify chronic neuroinflammation. This shift is increasing investment in novel mechanisms such as Bruton's tyrosine kinase (BTK) inhibition, remyelination strategies, neuroprotective therapies, cell-based approaches, and antigen-specific immune modulation. Clinical develop
The bipolar disorder treatment landscape is undergoing a structural transition as healthcare systems place greater emphasis on long-term disease stabilization rather than episodic symptom control. This shift exists because depressive episodes account for a substantial proportion of disease burden, creating demand for therapies that improve functional outcomes while maintaining acceptable safety profiles. Clinical development programs are increasingly targeting unmet needs in bipolar depressio
Bipolar disorder represents a persistent global mental health burden because recurrent manic, hypomanic, and depressive episodes continue affecting long-term functioning, employment, social participation, and quality of life. The disease affects an estimated 37 million people globally, creating sustained demand for psychiatric services, early diagnosis programs, pharmacological interventions, and psychosocial support systems. The patient landscape is shifting as health systems are expa
The bipolar disorder pipeline is entering a period of therapeutic diversification as developers move beyond traditional mood stabilizers and atypical antipsychotics. Demand for differentiated therapies remains strong because bipolar depression continues to represent the largest unmet clinical need across the treatment continuum. Development activity is increasingly targeting symptom domains that existing therapies do not adequately address, including cognitive dysfunction, functional impairme
The bipolar disorder therapeutic pipeline is entering a transition phase as developers move beyond symptom control toward disease-modifying and circuit-modulating approaches. The market structure remains anchored by mood stabilizers, atypical antipsychotics, and adjunctive psychiatric therapies, yet persistent relapse rates and incomplete response profiles are increasing demand for differentiated treatment options. This shift is encouraging sponsors to investigate glutamatergic modulation, ne
The bipolar disorder treatment landscape is entering a period of therapeutic diversification because unmet needs remain concentrated in bipolar depression, relapse prevention, and treatment-resistant disease. Existing mood stabilizers and atypical antipsychotics continue to dominate clinical practice, yet demand is shifting toward therapies that improve depressive symptoms without increasing metabolic burden or treatment discontinuation risk. This shift is increasing investment in novel mecha
The bipolar disorder drug pipeline is entering a transition phase because treatment demand increasingly centers on bipolar depression, relapse prevention, cognitive outcomes, and long-term tolerability rather than symptom suppression alone. Existing therapies remain dependent on mood stabilizers and atypical antipsychotics, while unmet needs continue to emerge across treatment-resistant populations and patients experiencing recurrent depressive episodes. Clinical development is therefore shif